908 Devices Announces New Data Integrations with Key Industry Partners to Accelerate BioProcess Data Insights
22 6월 2021 - 8:01PM
Business Wire
Integration of Sartorius SIMCA and Securecell
Lucullus PIMS with REBEL Spent Media Analyzer Allows for
Data-Driven Decisions and Real-time Value Extraction
908 Devices (NASDAQ:MASS), a pioneer of purpose-built handheld
and desktop mass spec devices for chemical and biomolecular
analysis, today announced two data analysis partnerships to
integrate with the REBEL™, the first at-line fresh and spent cell
media analyzer for bioprocess labs. With the integration of leading
data exploratory tool Sartorius’ SIMCA® and Securecell’s Lucullus
Process Information Management System (PIMS), users can seamlessly
turn REBEL data into deeper actionable insights to drive
operational excellence.
“We are focused on providing our customers the most actionable
bioanalytics information possible as simply as possible. In
integrating SIMCA and Lucullus with our REBEL platform, we are
providing connectivity into process and data analysis tools to help
our REBEL customers make informed decisions and be more effective
in their process development efforts,” said Steve Davenport, Vice
President of Commercial Sales for 908 Devices. “As our process
development customers focus on harnessing larger analytical data
sets, in part due to wealth of data now provided with REBEL, we
will continue to focus on helping them have the tools and methods
needed to mine the data and garner insights.”
908 Devices partnered with Sartorius to allow customers to
leverage the multivariate modelling used in SIMCA, which identifies
hidden trends and patterns not visible by univariate data analytic
methods. Here’s how REBEL customers can make data-driven decisions
faster with SIMCA:
- Seamless data flow from the REBEL into SIMCA to improve process
development analytics
- Improved data visualization, via interactive plots and direct
drill-down analytics, providing easy access to visualization and
interpretation of data patterns, expediting the identification of
nutrient trends
- Improved Quality by Design (QbD) approaches
908 Devices partnered with Securecell to empower REBEL users
with comprehensive Critical Process Parameter (CPP) monitoring and
data management, from raw material to the final product. Here’s how
REBEL customers can conduct more sophisticated data collection as
they monitor metrics of cell culture media with Lucullus:
- Streamlined UI and automated visualization of trends in fresh
or spent cell culture media for selection and rapid
optimization
- Ability to store all analytical results from medium quality
control testing in one place
- Simplified correlation of nutrients and metabolites through
streamlined data management, integrating with other data sources
across the bioprocess environment
Big data approaches, like the one discussed in our blog, may
accelerate drug pipelines to ensure that once a biologic is moved
into production, the process has already been engineered to deliver
high yields and batch-to-batch consistency. Such data mining
approaches are enabled with the integration of these two
well-known, broadly used software tools. REBEL users can now
visualize data and spot trends quickly and more easily. The REBEL
itself is disrupting bioprocess development with rapid at-line
analysis of cell culture media, empowering process development labs
with real-time analysis of cell media. Answers are delivered – not
just data – and users can use the device where they need it, right
beside their bioreactor rather than relying on the remote core lab
or third party service providers.
To learn more about the REBEL and 908 Devices, please visit:
https://908devices.com/.
About 908 Devices
908 Devices (NASDAQ:MASS) is democratizing laboratory mass
spectrometry with its simple handheld and desktop devices,
addressing critical-to-life applications. The Company’s devices are
used at the point-of-need to interrogate unknown and invisible
materials and provide quick, actionable answers to directly address
some of the most critical problems in life sciences research,
bioprocessing, pharma / biopharma, forensics, and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic separations, software
automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements,”
including statements relating to the Company’s new partnership
capabilities and the expected impact on drug pipelines.
Forward-looking statements involve known and unknown risks,
uncertainties and assumptions which may cause actual results to
differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in our
annual and quarterly reports and other filings that we make from
time to time with the SEC. Although the Company believes that the
expectations reflected in its forward-looking statements are
reasonable, it cannot guarantee future results. The Company has no
obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210622005188/en/
908 Devices Contact Katie Johnston PAN Communications for
908 Devices 908devices@pancomm.com
Investor Contact Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 7월(7) 2024 으로 8월(8) 2024
908 Devices (NASDAQ:MASS)
과거 데이터 주식 차트
부터 8월(8) 2023 으로 8월(8) 2024